left atrial appendage closure

Cierre de orejuela izquierda

Left Atrial Appendage Closure and Concomitant Transcatheter Intervention: Can We?

Several scientific societies support performing left atrial appendage occlusion (LAAO) as a stand-alone procedure, even though it is often associated to other cardiomyopathies requiring transcatheter intervention.&nbsp; Though still controversial, combining LAAO and any other cardiac intervention might reduce hospitalizations, as well as the need for additional punctures, anesthesia, red tape, a longer stay and higher<a href="https://solaci.org/en/2024/02/06/left-atrial-appendage-closure-and-concomitant-transcatheter-intervention-can-we/" title="Read more" >...</a>

TCT 2023 | ALIGN AR trial

TCT 2023 | SWISS-APERO: One-Year Events After Left Atrial Appendage Closure with Amulet or Watchman FLX Device

It has been observed that the persistence of an opening in the left atrial appendage after percutaneous closure (LAAC) is associated with a higher risk of embolic events. Among the most commonly used devices for left atrial appendage closure are the Watchman FLX and Amulet devices. This study, known as SwissApero, represents the first randomized<a href="https://solaci.org/en/2023/10/27/tct-2023-swiss-apero-one-year-events-after-left-atrial-appendage-closure-with-amulet-or-watchman-flx-device/" title="Read more" >...</a>

El cierre de orejuela es seguro con los nuevos dispositivos

Left Atrial Appendage Closure Is a Valid Option

Atrial fibrillation (AF) is the most frequent arrhythmia in patients &gt;55 years old and is related to ischemic stroke due to thrombi formation in the left atrium, particularly in the atrial appendage. To avoid this complication, anticoagulation is indicated, but patients &gt;75 years are at high risk of bleeding, making percutaneous closure of the atrial<a href="https://solaci.org/en/2022/11/03/left-atrial-appendage-closure-is-a-valid-option/" title="Read more" >...</a>

El cierre de orejuela es seguro con los nuevos dispositivos

Left Atrial Appendage Closure Is Safe with the New Devices

Left atrial appendage closure (LAAC) in non-valvular atrial fibrillation with high risk of bleeding has shown promising results with first generation devices (with the Watchman) in the different studies. At present, we have a more modern device, the Watchman FLX, but we do not have much information about it.&nbsp; To gather more data, researchers looked<a href="https://solaci.org/en/2022/08/18/left-atrial-appendage-closure-is-safe-with-the-new-devices/" title="Read more" >...</a>

DEFENSE-PFO: el cierre FOP con ciertas características disminuye eventos combinados y stroke

TRAPEUR Registry: Thrombus Trapping with Left Atrial Appendage Closure Device

Left atrial appendage closure (LAAC) devices are a good alternative for the prevention of systemic thromboembolism in patients with non-valvular atrial fibrillation (AF) and high risk of bleeding or those with anticoagulation contraindication.&nbsp; According to PRAGUE-17 outcomes, at 4 years, LAAC resulted non-inferior to direct anticoagulation in the prevention of cardiovascular, neurological, and bleeding events.&nbsp;<a href="https://solaci.org/en/2022/06/29/trapeur-registry-thrombus-trapping-with-left-atrial-appendage-closure-device/" title="Read more" >...</a>

cierre_orejuela_stroke

Left Atrial Appendage Closure vs Direct Anticoagulants at Long Term

The PRAGUE-17 has shown that left atrial appendage closure is not inferior to direct anticoagulants at long term to prevent major cardiovascular, neurological, or bleeding events. Moreover, procedures not related to prosthesis implantation saw significant reduction. The PRAGUE-17 was a randomized non-inferiority study comparing left atrial appendage closure (Watchman or Amulet) with direct anticoagulants (95%<a href="https://solaci.org/en/2022/01/14/left-atrial-appendage-closure-vs-direct-anticoagulants-at-long-term/" title="Read more" >...</a>

Resultados a 5 años del cierre de orejuela

Net Benefit of Left Atrial Appendage Closure vs. Anticoagulation in Atrial Fibrillation

This analysis shows that the long-term clinical benefit of left atrial appendage closure with Watchman is superior to warfarin in patients with atrial fibrillation (AF). The initial peri-procedural risks of device implantation are counterbalanced over time, with reduced risk of bleeding and death.&nbsp; The PROTECT-AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in<a href="https://solaci.org/en/2019/12/02/net-benefit-of-left-atrial-appendage-closure-vs-anticoagulation-in-atrial-fibrillation/" title="Read more" >...</a>

EWOLUTION: Outcomes of left atrial appendage closure in the real world

Original Title: EWOLUTION: 3-months outcome of Left Atrial Appendage Closure with the WATCHMAN device in Europe. Presenter: Martin Bergmann. &nbsp; This study presented the experience of left atrial appendage closure with the WATCHMAN device outside the selected population of prior randomized clinical trials. The study included more than 1000 patients in this single arm multicenter registry;<a href="https://solaci.org/en/2016/05/19/ewolution-outcomes-of-left-atrial-appendage-closure-in-the-real-world/" title="Read more" >...</a>

AMULET vs WATCHMAN. Los dispositivos de cierre de orejuela cabeza a cabeza

Left Atrial Appendage Closure with Watchman Device. 5 Year Outcomes

Original Title: Percutaneous Left Atrial Appendage Closure with the Watchman Device Long-Term Results Up to 5 Years. Reference: Wiebe J, Franke J, Lehn K et al. JACC Cardiovascular Interventions Vol. 8, NO. 15, 2015 Doi: 10.1016/j.jcin.2015.07.040 Courtesy of Dr. Agustín Vecchia. Atrial fibrillation (AF) is one of the most predominant arrhythmias and is associated to cardioembolic<a href="https://solaci.org/en/2016/01/25/left-atrial-appendage-closure-with-watchman-device-5-year-outcomes/" title="Read more" >...</a>

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

Cost-Effectiveness of Left Atrial Appendage Closure and the New Anticoagulants vs. Warfarin in Atrial Fibrillation

Original Title: Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF Warfarin vs. NOACs vs. LAA Closure. Reference: Vivek Y. Reddy et al. J Am Coll Cardiol. 2015;66(24):2728-2739. Left atrial appendage closure and the new anticoagulants (NOACs) have emerged as safe and effective alternatives to warfarin for stroke in patients with non-valvular atrial fibrillation. This analysis<a href="https://solaci.org/en/2015/12/23/cost-effectiveness-of-left-atrial-appendage-closure-and-the-new-anticoagulants-vs-warfarin-in-atrial-fibrillation/" title="Read more" >...</a>

Top